ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Transcriptomic network analysis and functional evidence identify a candidate EMT hub signature associated with nasopharyngeal carcinoma progression.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC) is a clinically aggressive malignancy in which epithelial-mesenchymal transition (EMT) plays a central role in invasion, metastasis, and therapeutic resistance. However, the coordinated transcriptional organization, regulatory mechanisms, and functional relevance of EMT-associated genes in NPC remain insufficiently defined. This study aimed to identify EMT-related hub genes in NPC and integrate multiomics and functional evidence to elucidate their biological and clinical significance. Weighted gene coexpression network analysis was performed on the GSE12452 dataset to identify EMT-associated modules and hub genes. Multiomics validation, including transcriptomic, protein level, methylation, mutation, CNV, survival, and drug response profiling, was conducted using GSCA, HPA, OncoDB, cBioPortal, and GDC databases. miRNA regulators were predicted using TargetScan and validated by dual-luciferase assays. Functional significance was assessed through RT-qPCR, Western blotting, apoptosis, viability, colony formation, and wound healing assays following treatment of NPC cells with afatinib or SB431542. WGCNA identified four EMT hub genes, VIM, SNAI1, ZEB1, and FN1, which were consistently overexpressed in NPC. These genes were hypomethylated, exhibited CNV alterations, and were associated with poor survival and broad drug resistance profiles. Predicted miRNA interactions were experimentally validated. Pharmacologic inhibition of EMT-associated signaling significantly reduced hub gene expression and suppressed malignant phenotypes across multiple NPC cell lines. This integrative analysis identifies VIM, SNAI1, ZEB1, and FN1 as a candidate EMT-associated hub signature linked with NPC progression, prognosis, and drug response patterns. Pharmacological inhibition of EMT-associated signaling reduced hub gene expression and suppressed malignant cellular phenotypes, suggesting that this EMT hub network may have potential value as a prognostic biomarker panel and as a putative therapeutic vulnerability requiring further validation.
Indexed as
Identifiers
42496704What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.